Show simple item record

dc.contributor.authorDuda, Dan Gabriel
dc.contributor.authorWillett, Calvin Winslow
dc.contributor.authorAncukiewicz, M
dc.contributor.authordi Tomaso, E.
dc.contributor.authorShah, M.
dc.contributor.authorCzito, B. G.
dc.contributor.authorBentley, R.
dc.contributor.authorPoleski, M.
dc.contributor.authorLauwers, Gregory Y.
dc.contributor.authorCarroll, M.
dc.contributor.authorTyler, D.
dc.contributor.authorMantyh, C.
dc.contributor.authorShellito, Paul Clarke
dc.contributor.authorClark, J. W.
dc.contributor.authorJain, R. K.
dc.date.accessioned2017-10-20T21:25:38Z
dc.date.issued2010
dc.identifier.citationDuda, D. G., C. G. Willett, M. Ancukiewicz, E. di Tomaso, M. Shah, B. G. Czito, R. Bentley, et al. 2010. “Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer.” The Oncologist 15 (6) (May 18): 577–583. doi:10.1634/theoncologist.2010-0029.en_US
dc.identifier.issn1083-7159en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34268579
dc.description.abstractWe explored plasma and urinary concentrations of two members of the vascular endothelial growth factor (VEGF) family and their receptors as potential response and toxicity biomarkers of bevacizumab with neoadjuvant chemoradiation in patients with localized rectal cancer. The concentrations of VEGF, placental growth factor (PlGF), soluble VEGF receptor 1 (sVEGFR-1), and sVEGFR-2 were measured in plasma and urine at baseline and during treatment. Pretreatment values and changes over time were analyzed as potential biomarkers of pathological response to treatment as well as for acute toxicity in patients with locally advanced rectal cancer treated prospectively in 2002–2008 with neoadjuvant bevacizumab, 5-fluorouracil, radiation therapy, and surgery in a phase I/II trial. Of all biomarkers, pretreatment plasma sVEGFR-1—an endogenous blocker of VEGF and PlGF, and a factor linked with “vascular normalization”—was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation. Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting.en_US
dc.language.isoen_USen_US
dc.publisherAlphamed Pressen_US
dc.relation.isversionofdoi:10.1634/theoncologist.2010-0029en_US
dash.licenseMETA_ONLY
dc.subjectbevacizumaben_US
dc.subjectsVEGFR-1en_US
dc.subjectbiomarkeren_US
dc.subjectrectal canceren_US
dc.subjectchemoradiationen_US
dc.subjecttoxicityen_US
dc.titlePlasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Canceren_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalThe Oncologisten_US
dash.depositing.authorLauwers, Gregory Y.
dash.embargo.until10000-01-01
dc.identifier.doi10.1634/theoncologist.2010-0029*
dash.authorsorderedfalse
dash.contributor.affiliatedLauwers, Gregory Y.
dash.contributor.affiliatedWillett, Calvin
dash.contributor.affiliatedShellito, Paul
dash.contributor.affiliatedAncukiewicz, Marek
dash.contributor.affiliatedDuda, Dan


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record